Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Vertex Pharmaceuticals
  6. Summary
    VRTX   US92532F1003

VERTEX PHARMACEUTICALS

(VRTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/10/2021 06/11/2021 06/14/2021 06/15/2021 06/16/2021 Date
216.77(c) 193.02(c) 194.8(c) 188.97(c) 189.99 Last
2 623 195 13 725 126 3 399 156 4 608 874 754 861 Volume
+1.50% -10.96% +0.92% -2.99% +0.54% Change
More quotes
Financials (USD)
Sales 2021 6 928 M - -
Net income 2021 1 882 M - -
Net cash position 2021 8 136 M - -
P/E ratio 2021 25,5x
Yield 2021 -
Sales 2022 7 703 M - -
Net income 2022 2 735 M - -
Net cash position 2022 11 081 M - -
P/E ratio 2022 18,1x
Yield 2022 -
Capitalization 48 918 M 48 918 M -
EV / Sales 2021 5,89x
EV / Sales 2022 4,91x
Nbr of Employees 3 400
Free-Float 99,9%
More Financials
Company
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination... 
Read more
More about the company
Ratings of Vertex Pharmaceuticals
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about VERTEX PHARMACEUTICALS
06/14VERTEX PHARMACEUTICALS  : SVB Leerink Adjusts Vertex Pharmaceuticals' Price Targ..
MT
06/14VERTEX PHARMACEUTICALS  : Truist Securities Adjusts Price Target on Vertex Pharm..
MT
06/14VERTEX PHARMACEUTICALS  : and CRISPR Therapeutics Present New Data in 22 Patient..
AQ
06/14VERTEX PHARMACEUTICALS  : Piper Sandler Adjusts Price Target on Vertex Pharmaceu..
MT
06/11AFTER HOURS WATCH LIST SCORECARD : Pgen, tyme, vrtx
MT
06/11Vertex, Incyte fall; Precigen, Magnachip rise
AQ
06/11SECTOR UPDATE : Health Care Stocks Roughed Up Heading into Friday Close
MT
06/11VERTEX PHARMACEUTICALS  : Pharma Sheds 10% After VX-864 Drug Candidate Disappoin..
MT
06/11SECTOR UPDATE : Health Care Stocks Swinging Between Slim Gains, Declines
MT
06/11Stocks Retreat Midday Amid Inflation Worries
MT
06/11MIDDAY REPORT : Wall Street Retreats Midday Amid Inflation Worries
MT
06/11Vertex Pharmaceuticals Down Over 8%, Worst Performer in The S&P 500 and Nasda..
DJ
06/11Vertex Won't Move VX-864 into Late-Stage Testing After Disappointing Study Re..
MT
06/11VERTEX PHARMACEUTICALS  : Goldman Sachs Adjusts Price Target on Vertex Pharmaceu..
MT
06/11JPMorgan Adjusts Price Target on Vertex Pharmaceuticals to $245 From $279, Ma..
MT
More news
News in other languages on VERTEX PHARMACEUTICALS
06/11BOLSA  : Madrid cierra al alza al descontarse que aceleración inflación será tem..
04/26VERTEX : NaV1.8-Inhibitor erreicht Phase 2 der klinischen Entwicklung
04/26VERTEX PHARMACEUTICALS  : annonce que l'inhibiteur NaV1.8 a progressé vers un dé..
04/23DGAP-NEWS : BB BIOTECH AG: Erfolgreiche -2-
03/10VERTEX PHARMACEUTICALS  : gibt Erteilung des Fast-Track-Status durch die FDA und..
More news
Analyst Recommendations on VERTEX PHARMACEUTICALS
More recommendations
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Average target price 261,78 $
Last Close Price 188,97 $
Spread / Highest target 75,2%
Spread / Average Target 38,5%
Spread / Lowest Target 5,84%
EPS Revisions
Managers and Directors
NameTitle
Reshma Kewalramani President, Chief Executive Officer & Director
Charles F. Wagner Chief Financial Officer & Executive Vice President
Jeffrey M. Leiden Executive Chairman
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Carmen Bozic Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS-20.04%48 918
GILEAD SCIENCES, INC.16.87%85 472
WUXI APPTEC CO., LTD.28.23%66 801
REGENERON PHARMACEUTICALS9.19%54 755
BIONTECH SE167.63%53 275
BEIGENE, LTD.28.49%31 729